Cargando…
Shifting drug markets in North America - a global crisis in the making?
Understanding drug market dynamics and their underlying driving factors is paramount to developing effective responses to the overdose crisis in North America. This paper summarises the distinct drug market trends observed locally and internationally over the past decade to extrapolate future drug m...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598952/ https://www.ncbi.nlm.nih.gov/pubmed/37880722 http://dx.doi.org/10.1186/s13033-023-00601-x |
_version_ | 1785125669548589056 |
---|---|
author | Meyer, Maximilian Westenberg, Jean N. Jang, Kerry L. Choi, Fiona Schreiter, Stefanie Mathew, Nickie King, Conor Lang, Undine E. Vogel, Marc Krausz, R. Michael |
author_facet | Meyer, Maximilian Westenberg, Jean N. Jang, Kerry L. Choi, Fiona Schreiter, Stefanie Mathew, Nickie King, Conor Lang, Undine E. Vogel, Marc Krausz, R. Michael |
author_sort | Meyer, Maximilian |
collection | PubMed |
description | Understanding drug market dynamics and their underlying driving factors is paramount to developing effective responses to the overdose crisis in North America. This paper summarises the distinct drug market trends observed locally and internationally over the past decade to extrapolate future drug market trajectories. The emergence of fentanyl on North American street markets from 2014 onwards led to a shift of street drug use patterns. Previously perceived as contaminants, novel synthetic opioids became the drugs of choice and a trend towards higher potency was observed across various substance classes. The diversification of distribution strategies as well as the regionalisation and industrialisation of production followed basic economic principles that were heavily influenced by prosecution and policy makers. Particularly, the trend towards higher potency is likely most indicative of what to expect from future illicit drug market developments. Nitazenes and fentanyl-analogues, several times more potent than fentanyl itself, are increasingly detected in toxicological testing and have the potential of becoming the drugs of choice in the future. The dynamic of drug import and local production is less clear and influenced by a multitude of factors like precursor availability, know-how, infrastructure, and the success of local drug enforcement strategies. Drug market dynamics and the current trajectory towards ultrapotent opioids need to be recognised by legislation, enforcement, and the health care system to prepare effective responses. Without significant improvements in treatment access, the implementation of preventative approaches and early warning systems, the mortality rate will continue to increase. Furthermore, there is no mechanism in place preventing the currently North American focused overdose crisis to spread to other parts of the globe, particularly Europe. A system of oversight, research, and treatment is needed to address mortality rates of historic proportions and prevent further harm. |
format | Online Article Text |
id | pubmed-10598952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105989522023-10-26 Shifting drug markets in North America - a global crisis in the making? Meyer, Maximilian Westenberg, Jean N. Jang, Kerry L. Choi, Fiona Schreiter, Stefanie Mathew, Nickie King, Conor Lang, Undine E. Vogel, Marc Krausz, R. Michael Int J Ment Health Syst Comment Understanding drug market dynamics and their underlying driving factors is paramount to developing effective responses to the overdose crisis in North America. This paper summarises the distinct drug market trends observed locally and internationally over the past decade to extrapolate future drug market trajectories. The emergence of fentanyl on North American street markets from 2014 onwards led to a shift of street drug use patterns. Previously perceived as contaminants, novel synthetic opioids became the drugs of choice and a trend towards higher potency was observed across various substance classes. The diversification of distribution strategies as well as the regionalisation and industrialisation of production followed basic economic principles that were heavily influenced by prosecution and policy makers. Particularly, the trend towards higher potency is likely most indicative of what to expect from future illicit drug market developments. Nitazenes and fentanyl-analogues, several times more potent than fentanyl itself, are increasingly detected in toxicological testing and have the potential of becoming the drugs of choice in the future. The dynamic of drug import and local production is less clear and influenced by a multitude of factors like precursor availability, know-how, infrastructure, and the success of local drug enforcement strategies. Drug market dynamics and the current trajectory towards ultrapotent opioids need to be recognised by legislation, enforcement, and the health care system to prepare effective responses. Without significant improvements in treatment access, the implementation of preventative approaches and early warning systems, the mortality rate will continue to increase. Furthermore, there is no mechanism in place preventing the currently North American focused overdose crisis to spread to other parts of the globe, particularly Europe. A system of oversight, research, and treatment is needed to address mortality rates of historic proportions and prevent further harm. BioMed Central 2023-10-25 /pmc/articles/PMC10598952/ /pubmed/37880722 http://dx.doi.org/10.1186/s13033-023-00601-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Comment Meyer, Maximilian Westenberg, Jean N. Jang, Kerry L. Choi, Fiona Schreiter, Stefanie Mathew, Nickie King, Conor Lang, Undine E. Vogel, Marc Krausz, R. Michael Shifting drug markets in North America - a global crisis in the making? |
title | Shifting drug markets in North America - a global crisis in the making? |
title_full | Shifting drug markets in North America - a global crisis in the making? |
title_fullStr | Shifting drug markets in North America - a global crisis in the making? |
title_full_unstemmed | Shifting drug markets in North America - a global crisis in the making? |
title_short | Shifting drug markets in North America - a global crisis in the making? |
title_sort | shifting drug markets in north america - a global crisis in the making? |
topic | Comment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598952/ https://www.ncbi.nlm.nih.gov/pubmed/37880722 http://dx.doi.org/10.1186/s13033-023-00601-x |
work_keys_str_mv | AT meyermaximilian shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT westenbergjeann shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT jangkerryl shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT choifiona shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT schreiterstefanie shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT mathewnickie shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT kingconor shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT langundinee shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT vogelmarc shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking AT krauszrmichael shiftingdrugmarketsinnorthamericaaglobalcrisisinthemaking |